Ruxolitinib + Extracorporeal photopheresis (ECP) + Low-dose methotrexate (MTX) + Mycophenolate mofetil (MMF) + mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) + Infliximab + Rituximab + Pentostatin + Imatinib + Ibrutinib
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Graft-versus-host Disease (GVHD)
Conditions
Graft-versus-host Disease (GVHD)
Trial Timeline
Jun 29, 2017 → Dec 15, 2022
NCT ID
NCT03112603About Ruxolitinib + Extracorporeal photopheresis (ECP) + Low-dose methotrexate (MTX) + Mycophenolate mofetil (MMF) + mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) + Infliximab + Rituximab + Pentostatin + Imatinib + Ibrutinib
Ruxolitinib + Extracorporeal photopheresis (ECP) + Low-dose methotrexate (MTX) + Mycophenolate mofetil (MMF) + mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) + Infliximab + Rituximab + Pentostatin + Imatinib + Ibrutinib is a phase 3 stage product being developed by Incyte for Graft-versus-host Disease (GVHD). The current trial status is completed. This product is registered under clinical trial identifier NCT03112603. Target conditions include Graft-versus-host Disease (GVHD).
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03112603 | Phase 3 | Completed |
Competing Products
20 competing products in Graft-versus-host Disease (GVHD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Alefacept | Astellas Pharma | Phase 2 | 52 |
| EQ001 + EQ001 Placebo | Biocon | Phase 1/2 | 41 |
| SHR0302 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| Prednisone + Jakavi(ruxolitinib) + Prednisone | Novartis | Phase 2 | 52 |
| PredEver | Novartis | Phase 2 | 52 |
| Lifitegrast 5% Ophthalmic Solution + Placebo | Novartis | Phase 1 | 33 |
| LBH589 + Methylprednisolone | Novartis | Phase 2 | 52 |
| Panobinostat (LBH589) | Novartis | Phase 1/2 | 41 |
| Filgrastim | Amgen | Pre-clinical | 22 |
| AMG 592 | Amgen | Phase 1 | 32 |
| AMG 592 | Amgen | Phase 1 | 32 |
| BMS-986004 + Sirolimus + Tacrolimus | Bristol Myers Squibb | Phase 1 | 32 |
| Belumosudil (KD025) | Sanofi | Phase 2 | 51 |
| Belumosudil 200 mg QD + Belumosudil 200 mg BID + Belumosudil 400 mg QD | Sanofi | Phase 2 | 51 |
| AAT + Placebo | CSL | Phase 2/3 | 64 |
| Ruxolitinib + Methylprednisolone | Incyte | Phase 2 | 49 |
| Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF) | Incyte | Phase 3 | 74 |
| Itacitinib + Corticosteroids | Incyte | Phase 1/2 | 38 |
| Ruxolitinib | Incyte | Pre-clinical | 20 |
| Itacitinib + Corticosteroid | Incyte | Phase 1 | 30 |